Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases

• Status: Completed
• Trial end date: 2006-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Single centre recruiting approximately 80 patients who are given a rising single, followed by multiple, ascending oral dose of AZD2171, assessing the safety and tolerability of AZD2171 in patients with solid tumors and metastatic liver disease.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Cediranib

Criteria

Inclusion Criteria:

• Provision of written informed consent

• Male/female, 18 yr or over

• WHO status 0-2

• Refractory advanced solid tumor

Exclusion Criteria:

• Radiotherapy within 4 weeks of starting AZD2171 treatment

• Low haemoglobin level

• Low platelet or neutrophil counts